Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 13/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.52 |
| ▸ | PPARD | Q03181 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16945286 | 0.95 | PPARA (0.49) | MAPK14PPARAPPARGPPARDHTT | |
| SCHEMBL16949298 | 0.92 | PPARA (0.52) | PPARAPPARGPPARDHTTSMN1; SMN2 | |
| SCHEMBL16945334 | 0.92 | MAPK14 (0.52) | MAPK14PPARAPPARGPPARDMMP13 | |
| SCHEMBL16945328 | 0.89 | MAPK14 (0.50) | MAPK14PPARAPPARGPPARDHTT | |
| SCHEMBL16945268 | 0.89 | MAPT (0.53) | MAPK14PPARAHTTSMN1; SMN2KDM4E | |
| SCHEMBL16945285 | 0.87 | PPARA (0.53) | PPARAPPARGPPARDHTTSMN1; SMN2 | |
| SCHEMBL15422871 | 0.87 | SMN1; SMN2 (0.50) | MAPK14PPARAPPARDHTTSMN1; SMN2 | |
| SCHEMBL16945306 | 0.85 | PPARG (0.48) | PPARAPPARGPPARDHTTSMN1; SMN2 | |
| SCHEMBL16945315 | 0.85 | AHR (0.49) | PPARASMN1; SMN2LMNA | |
| SCHEMBL16945290 | 0.85 | CHRM4 (0.51) | PPARAPPARGPPARDCHRM4PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875029-B1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | MORASKI GARRETT (US) | 2021-11-10 | — | — | EP | disclosed |
| US-9605002-B2 | 5,5-heteroaromatic anti-infective compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605002-B2 | 5,5-heteroaromatic anti-infective compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC | 2015-07-30 | — | — | US | disclosed |
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | API5, CASP5, IL5 | MAPK14 3090/4885PPARA 386/4885PPARG 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.